iPSCs. The therapy has resulted in positive results, stopping macular degeneration and improving the vision of the patient. Although the trial was subsequently put on hold due to mutations observed in a second patient’s iPSCs4, it is expected to resume6. In addition, a recent study has demonstrated the feasibility of transplanting human ESC-derived cardiac progenitor cells embedded in a fibrin scaffold to patients with severe heart failure152.
